Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria
Status:
Withdrawn
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study will test the effectiveness of two medications: ACEI (angiotensin converting
enzyme inhibitor)and ARB (angiotensin receptor blocker) in reducing the renal injury induced
by hyperoxaluria in patients with Primary Hyperoxaluria.
Hypothesis: Calcium oxalate crystal deposition in the kidney causes inflammation and
resulting injury to kidney tissue. Angiotensin blockade will improve these changes, thus
slowing the progression of renal insufficiency in patients with Primary Hyperoxaluria.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)